PAPRAT
Financiado
PAPRAT Predictive Algorithm for Pre Rheumatoid Arthritis Treatment . The new a...
PAPRAT Predictive Algorithm for Pre Rheumatoid Arthritis Treatment . The new and most efficient multiple biomarkers based system for an early selection of RA treatment intensity
Rheumatoid arthritis (RA) affects 1% of world population (17.6 M) and it is a relevant economic burden (€45 Bn spent yearly in Europe). It is a degenerative disease that affects bone health, cause joints’ deformity, impact other o...
Rheumatoid arthritis (RA) affects 1% of world population (17.6 M) and it is a relevant economic burden (€45 Bn spent yearly in Europe). It is a degenerative disease that affects bone health, cause joints’ deformity, impact other organs and cause disability. An early and personalized treatment can greatly improve its outcome, achieve remission and reduce pain, thus an accurate prognosis is critical for its efficient management. However, this is difficult for the lack of good prognosis factors (currently rheumatoid factor-RF or anti-citrullinated protein antibodies-ACPA), which at present are very few, poorly accurate and leave 40% of patients unclassified (suffering health complications due to an unnecessary aggressive treatment or from deterioration due to delays in proper treatment). Making Genetics is a Spanish start-up focused in personalized medicine through genomic approaches. We have designed and developed a prognostics test for RA based on a blood test and the use of our new PAPRAT algorithm, with 82.4% accuracy. PAPRAT is a multiple biomarker-based system capable of classifying pre-rheumatoid arthritis patients, discerning which will need a more aggressive treatment. It combines unique genomic markers (genetic and epigenetic), as well as clinical and demographical variables, to calculate a predictive index and classify patients’ RA severity as HIGH (needing early administration of a combined therapy with biological DMARDs) or LOW and MEDIUM (non-biological DMARDs are enough). It is at a TRL6 and now we aim to optimize it, further validate it, develop a software platform and prepare its market launch. RA is expected to grow by drivers such as an ageing population or the continued uptake of biosimilars, and we have currently a total addressable market of 17.6 M patients globally and of around 3M in Europe. We will offer a complete prognosis service, including the blood testing, as well as the licensing of our software platform once it is finished.
ver más
Duración del proyecto: 6 meses
Fecha Inicio: 2019-08-02
Fecha Fin: 2020-02-29
Fecha Fin: 2020-02-29
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2020-02-29
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
MAKING GENETICS
Constituye el objeto social: a. la prestación de servicios de medicina personalizada. b. la identificación y comercialización de nuevos biom...
Perfil tecnológico
TRL
4-5
50K
Perfil tecnológico
TRL
4-5
50K